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HIV-associated Opportunistic Infections in
Adults and Adolescents in the Era of HAART
David Paar, M.D.*, Associate Professor of Medicine, UTMB Department of Medicine, Division of
Infectious Diseases

Prior to the advent of Highly Active Antiretroviral increased number of AIDS cases, the overall
Therapy (HAART) in 1996, opportunistic infec- incidence of OIs has declined in patients receivtions (OIs) were an inevitable complication of ing HAART and appropriate preventive therapy
HIV infection, particularly in those patients with a for OIs. This reflects both the widespread use of
CD4 count of less than 200
effective preventative treatments
cells/mm3. Because of the considerCarefully designed for common OIs, and the effectiveable morbidity and mortality associness of HAART in preventing proated with OIs, medical research OI prophylaxis and found immunosuppression in
identified and developed drugs that
those with HIV infection.
treatment trials
were active against many of the
resulted in major OIs may occur as an acute preinfections that complicate AIDS.
Carefully designed OI prophylaxis
sentation of previously undiagadvances in the
and treatment trials resulted in
nosed HIV infection or may commajor advances in the management management of OIs. plicate the course of known HIV
of OIs. Although OI trials continue to
infection. Instituting an appropribuild on this foundation of knowledge, the focus ate antimicrobial based on the patient's CD4
of HIV clinical research has shifted to antiretrovi- count can reliably prevent certain OIs. Table 1
ral therapy since HAART can prevent and/or summarizes the infections, CD4 thresholds, and
reverse the immunological abnormalities that agents for primary (instituted prior to the occurlead to the development of OIs.
rence of active disease) and secondary (instituted after the an episode of active disease to preWith the introduction of HAART, HIV-infected vent recurrences) prevention of OIs.4
individuals have experienced declining rates of
HIV-related deaths. However, there are some A full description of the presentation, clinical
notable differences between the U.S. general course, methods of diagnosis, and treatment of
population and those who are incarcerated. For each OI is beyond the scope of this article; howthe year 2000, the overall rate of confirmed AIDS ever, it is important for HIV providers to have a
cases in state and federal prisons was four times quick and reliable source of prevention and treatthat of the general population.1 As a result, cor- ment information on hand. Some useful pocket
rectional health care workers are more likely to guides are: The Sanford Guide to HIV/AIDS
encounter OIs in their HIV-infected populations Therapy4 (published yearly) and Medical
than will health care professionals working out- Management of HIV Infection, (2003).7 Online
side of jails and prisons. This month's main arti- sources of treatment information can be found
cle focuses on new trends and clinical concepts at
http://www.AIDSinfo.nih.gov
(formerly,
in the occurrence of OIs that have accompanied http://www.hivatis.org).4,5
effective antiretroviral therapy, as well as up-todate information on prophylaxis and treatment of
Continued on page 2
OIs.

WHAT’S INSIDE

An Overview of Opportunistic
Infections
Since the introduction of HAART, there has been
a dramatic decline in both the number of deaths
due to AIDS and new diagnoses of AIDS.
Overall, this has resulted in an increasing number of patients living with AIDS.2 Despite the
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TABLE 1: Primary Prophylaxis for AIDS-associated OIs*
Pathogen

CD4 Count First-line
(cells/mm3) Prophylaxis

Alternatives

Comment

Pneumocystis
carinii

< 200

Trimethoprim-sulfamethoxazole
(TMP-SMX) DS 1
po qd

TMP-SMX SS 1
po qd; dapsone
100 mg po qd;
aerosolized pentamidine 300 mg
po q month; atovaquone 1500 mg
po qd

Patients may tolerate oral TMP-SMX
at prophylactic
doses even if rash
or other side
effects occurred
with higher doses.

Toxoplasma
gondii

< 100

TMP-SMX DS 1
po qd

TMP-SMX SS 1
po qd; dapsone
100 mg po qd +
pyrimethamine 50
mg po q week +
folinic acid 25 mg
po q week

Some clinicians
omit folinic acid if
significant leucopenia is not present at baseline.

Mycobacterium
avium-intracellulare

< 50

Azithromycin 1200
mg po q week or
clarithromycin 500
mg po bid

Rifabutin 300 mg
po qd
Note: contraindicated with some
ARVs; dose
adjustment may
be needed with
others

Azithromycin powder, 1000 mg
sachet dissolved
in H20 is used in
TX D.O.C. and is
effective and less
expensive than
1200 mg dose.

Cytomegalovirus
retinitis (CMV)

< 50

Valganciclovir 900 Oral ganciclovir
1000 mg po tid
mg po qd

Most clinicians
observe for CMV
retinitis or institute
prophylaxis based
on positive serum
PCR for CMV.

Candida species, < 50
cryptococcus
neoformans

Fluconazole 100200 mg po qd

Routine prophylaxis not recommended; may be instituted if recurrent
thrush, vaginitis, or
esophagitis.

+ PPD-tuberculin Any CD4
skin test (> 5
count
mm), or exposure to M. tuberculosis

INH 5mg/kg po qd
+ pyridoxine 50
mg po qd x 9
months or INH 15
mg/kg po + pyridoxine 100 mg po
twice weekly for 9
months. DOT is
preferred method
of administration

(continued from page 1)

Some OIs require secondary prophylaxis to
prevent recurrence. Secondary prophylaxis
is usually a continuation of the medications
used to treat the OI, sometimes at reduced
dosages. For example, disease due to disseminated MAC can be primarily prevented
with azithromycin 1200 mg po once per
week. If active disease develops, the treatment regimen consists of a combination of
at least two drugs. Secondary prophylaxis
must be maintained for an indefinite period
of time in order to prevent recurrence of the
infection.
In the pre-HAART era, the infectious agent
of many OIs could not be eliminated from
the body by a discrete course of treatment
because of severe underlying immunodeficiency. Therefore, therapy had to be maintained for an indefinite period, often lifelong.
In the era of HAART, the continued need for
primary or secondary prophylaxis is determined by the degree of immune reconstitution.

2
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Immune Reconstitution
The immunodeficiency that is associated
with untreated HIV infection is complicated
and leads to both a decline in CD4 cell numbers and to impairments in CD4 cell function. CD4 cells may lose the ability to
respond to many foreign antigens, and
these responses are lost in a somewhat predictable sequential fashion. For example,
the ability to respond to Pneumocystis carinii
antigens is lost well before the ability to
respond to herpesvirus antigens or CMV
antigens. Thus, serious herpesvirus and
CMV infections generally occur later in HIV
disease than PCP.
When viral replication is suppressed in
response to HAART, the initial rise in CD4
cells that occurs in the first one to three
months is largely due to a redistribution of
CD4 cells from the reticuloendothelial system and other tissue reservoirs. If HAART is
not initiated until severe CD4 cell depletion
has occurred, the CD4 cells that make their
way back into the circulation may not have
the ability to respond to common antigens.
As a result of CD4 cell redistribution, immediate exacerbations of pre-existing, subclinical OIs such as CMV retinitis or tuberculosis
may occur as the newly circulating CD4 cells
respond to these pathogens. These redistributed CD4 cells may cause inflammatory
responses to pathogens that were previousContinued on page 4

Two-month course
of PZA + rifampin
or rifabutin has
resulted in significant liver injury,
Either rifampin 600 prompting CDC to
mg po or rifabutin recommend q 2300 mg po qd x 4 week laboratory
monitoring if this
months
regimen is used.
Consider DOT and
Rifampin may be
dispensing only 2
contraindicated
with some ARVs, weeks worth at a
rifabutin may be
time
substituted
INH 5mg/kg po qd
+ pyridoxine 50
mg po qd x 6
months

www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a4.htm
www.cdc.gov/hiv/pubs/mmwr/tb.htm
www.cdc.gov/mmwr/preview/mmwrhtml/00044186.htm
*Adapted from The Sanford Guide to HIV/AIDS Therapy, 2003
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Faculty Disclosure

Letter from the Editor
Dear Correctional Colleagues:
As AIDS therapy marches into the new millennium, we have witnessed a dramatic decrease
in AIDS mortality and a corresponding increase in the number of patients living with AIDS.
There is no doubt that Highly Active Antiretroviral Therapy (HAART) has benefited HIVinfected persons over the years, however the number of AIDS cases is still high and opportunistic infections (OIs) are still a common occurrence, particularly in the correctional population.
This month’s lead article by Dr. David Paar discusses new trends and clinical concepts in
the occurrence of OIs that have accompanied effective antiretroviral therapy. This informative review provides up-to-date information on prevention and treatment of OIs. Immune
reconstitution - a concept that often receives too little attention in HIV-disease research is given its due by Dr. Paar in his accessible explication of immunotherapeutic strategies
that can be used following HAART-associated immune reconstitution. A review of correctional-specific issues surrounding prevention and treatment of OIs, as well as educational
initiatives in jails and prisons, is a keen reminder that education is a continuous process,
often most effective when delivered in tailor-made and creative ways.
In the Spotlight for October Ms. Abby Dees provides timely discussion of clustering in U.S.
correctional facilities. This article weighs the pros and cons of the practical aspects of segregating HIV-infected inmates and describes the areas of law that address this delicate and
litigious issue.
After reading this month’s issue you should be more familiar with the prevention and treatment of OIs since the advent of HAART, concepts in immune reconstitution and the subtleties of multi-drug resistant tuberculosis. Next month’s HEPP Report will feature comprehensive coverage of the ICCAAC (Interscience Conference on Antimicrobial Agents and
Chemotherapeutics), the 41st Annual Meeting of the IDSA (Infectious Diseases Society of
America), the NCCHC (National Conference on Correctional Healthcare), and the
CEECDISP (Central and Eastern European Conference on Drug Infection Services in
Prison).
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TABLE 2: OIs for which prophylaxis or maintenance therapy can be
discontinued following HAART-associated immune reconstitution*

(continued from page 2)

ly present. These reactions are called
immune reconstitution syndromes.
Following the initial increase in CD4 cells
attributed to redistribution, there is a more
gradual and sustained increase in these
cells due to the emergence of naïve CD4
cells that have the ability to develop a full
array of immune responses to various foreign antigens. This differentiation of cells
takes time, which is why recommendations
regarding stopping prophylaxis for various
OIs is based not only on a rise in CD4 numbers to certain thresholds, but also a period
of sustained increase that allows the naïve
cells to develop into clones that can respond
to specific foreign antigens (Table 2).7

Tuberculosis
The Official Joint Statement for the
Treatment of Tuberculosis of the American
Thoracic Society, CDC, and the Infectious
Diseases Society of America was approved
in October 2002, published in 20036,8 and
may be accessed through the CDC website
(www.cdc.gov). Treatment regimens for
tuberculosis are summarized in Table 3. For
a more complete discussion of the diagnosis, prevention, and treatment of tuberculosis, refer to the February 2003 issue of
HEPP Report.

Correctional-Specific Issues
Relative to the Prevention
and Treatment of OIs
Educational efforts are most effective when
they are tailored to the population being
served. For incarcerated HIV-infected
patients, this includes being aware of literacy skills, English language competency, and
cultural beliefs about disease and medical
treatment. Education can be provided in
many ways, including verbally from the treating clinician, in written form via handouts, in
video format in clinic waiting areas or over
the facility television system, and through
peer-to-peer teaching.
The most successful approach integrates
multiple strategies, and reinforces the message at each patient encounter. Asking the
patient to name all of his or her medications
(and the reason that s/he takes them) at
each visit is one helpful way to assess
patient knowledge.

Self-Administered Keep On
Person (KOP) vs. Directly

Opportunistic Infection

Immune Reconstitution Parameter and Comment

PCP

Prophylactic or preventive therapy can be safely stopped when
CD4 count rises to > 200 cells/mm3 for at least 3 consecutive
months.

MAI or MAC

Primary MAC prophylaxis can be discontinued in patients who
have responded to HAART and have an increase in CD4 cells
to > 100 cells/mm3. Secondary prophylaxis can be discontinued after 12 months of successful therapy and when there is an
increase in CD4 cells to > 100 cells/mm3 for > 6 months.

Cryptococcal disease

Following an initial successful course of therapy and in the
absence of symptoms attributable to cryptococcal disease,
maintenance therapy can probably be stopped when there has
been a sustained increase in CD4 cells to 100-200 cells/mm3
for at least 6 months. Some, but not all, experts recommend
performing LP and demonstrating negative culture prior to discontinuing maintenance therapy. Reinitiate maintenance if CD4
count falls below 100-200 cells/mm3.

Toxoplasmic encephalitis Primary prophylaxis can be discontinued when CD4 count rises
to > 200 cells/mm3 for at least 3 consecutive months. Following
an initial successful course of therapy and in the absence of
symptoms attributable to toxoplasmic encephalitis, maintenance
therapy can probably be stopped when there has been a sustained increase in CD4 cells to > 200 cells/mm3 for > 6 months.
Some experts recommend that MRI scanning be done to aid in
the decision to stop chronic maintenance therapy. Resume
maintenance if CD4 falls below 200 cells/mm3 .
CMV retinitis

Maintenance therapy can be discontinued safely in patients
whose CD4 cells have shown a sustained increase to > 100150 cells/mm3 for > 6 months.

*Adapted from 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons
Infected with Human Immunodeficiency Virus.

Observed Therapy (DOT)
There are compelling reasons to utilize both
DOT and KOP methods of medication delivery (see Table 4). Each facility should evaluate these and other factors and come to a
decision that best meets the needs of their
program and patient population. One hybrid
option is to start all patients on DOT, and
then offer KOP to those who 1) demonstrate
adherence by maintaining an undetectable
HIV viral load over time, and 2) are able to
correctly describe their medications and
dosing schedule.

Quality Review
The provision of quality care to HIV-infected
patients demands careful attention to detail.
Multi-drug regimens, the potential for drugdrug interactions, and the necessity of close
monitoring of laboratory data can overwhelm
any paper record system. The use of a computerized database can enable clinicians to
rapidly review HAART regimens, detect
potential adverse interactions, and track

those patients who are candidates for initiating or discontinuing OI prophylaxis. An
upcoming issue of HEPP Report will review
some of the software programs that are currently in use in major correctional health
care systems nationwide.

Summary
The incidence of AIDS and AIDS-associated
deaths and diagnoses in the U.S. has
declined significantly in both the general
population and the correctional population
due to the introduction of HAART in clinical
HIV practice. Nonetheless, the number of
AIDS cases is high and OIs are still a common occurrence. In the correctional population, OIs occur more frequently than in the
general U.S. population. Many OIs can be
prevented with the appropriate preventive
therapy. When OIs do occur, various treatment regimens are effective; however secondary prophylaxis is often indicated unless
Continued on page 5
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the immune system becomes reconstituted
in response to HAART. TB disease is especially problematic in the correctional setting
because of the risk of transmission to others, the occurrence of drug-resistant strains
of Mycobacteria tuberculosis and the potential interactions between anti-tuberculosis
and antiretroviral medications.
Disclosures:
*Consultant: Ortho Biotech
Grant/Research Support: GlaxoSmithKline,
Agouron, Merck, DCHD, Serono,
Gilead, Chiron Corp. Boehringer Ingleheim,
Abbott Labs, Bristol-Myers Squibb
Speaker's Bureau: Roche, Bristol-Myers
Squibb, OrthoBiotech
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1. HIV in Prisons, 2000, U.S. Department of
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www.ojp.usdoj.gov/bjs/abstract/hivp00.htm.
2. Update: AIDS --- United States, 2000,
Morbidity and Mortality Weekly Report
(MMWR), July 12, 2002:51(27);592-595,
available at:
www.cdc.gov/mmwr/preview/mmwrhtml/
mm5127a2.htm
3. Palella FJ Jr., Delaney KM, Loveless AC,
et al., Declining Morbidity and Mortality
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Immunodeficiency Virus Infection, New
EnglJ Med 1998:338 (13);853-860.
4. Sande MA, Moellering RC Jr., and
Gilbert DN, The Sanford Guide to HIV/AIDS
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Mortality Weekly Report (MMWR),
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TABLE 3: Drug Regimens for Treatment of Culture Positive
Pulmonary Tuberculosis*
INITIAL PHASE
Regi Drugs Interval and doses#
men
(minimal duration and

CONTINUATION PHASE
Regi Drugs
Interval and dosages#
men
(minimal duration and range of doses)

range of doses)

1

INH
RIF
PZA
EMB

Seven days per week
for 56 doses or 5 days
per week for 40 doses.

1a

INH/RIF Seven days per week for 126
doses or 5 days per week for 90
doses (18 weeks).
1b & INH/RIF Twice weekly for 36 doses (18
weeks).
1c% INH/RPT Once weekly for 18 doses (18
weeks).

2

INH
RIF
PZA
EMB

Seven days per week
for 14 doses then twice
weekly for 12 doses or
5 days per week for 10
doses then twice weekly for 12 doses.

2a & INH/RIF Twice weekly for 36 doses (18
weeks).
2b% INH/RPT Once weekly for 18 doses (18
weeks).

3

INH
RIF
PZA
EMB

Three times weekly for
24 doses.

3a

INH/RIF Three times weekly for 54 doses
(18 weeks).

4

INH
RIF
EMB

Seven days per week
for 56 doses or 5 days
per week for 40 doses.

4a

INH/RIF Seven days per week for 217
doses or 7 days per week for 155
doses (31 weeks).
INH/RIF Twice weekly for 62 doses (31
weeks).

4b

*Adapted from Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases
Society of America6,8
abbreviations of drugs: INH = isoniazid; RIF = rifampin; RPT = rifapentine; PZA =pyrazinamide; EMB =
ethambutol.
# When directly observed therapy (DOT) is used, drugs may be given 5 days per week and number of
dosages adjusted accordingly.
$ Patients with cavitation on initial chest radiograph and positive cultures at completion 2 months of initiation should receive a 7-month continuation phase at either daily or twice weekly dose interval.
& Not recommended for HIV positives with a CD4 cell count < 100 cells/mm3
% Not recommended for HIV positives or HIV negatives or for HIV negatives who do not have negative
sputum smears at the end of initiation or who have cavitation of initial chest radiograph.

TABLE 4: Self-Administered Keep On Person (KOP) vs. Directly
Observed Therapy (DOT)
Keep On Person

Directly Observed Therapy

+ Increases patients' autonomy

+ Easier to assess accurately adherence

+ Less staff-intensive

+ Better for forgetful patients

+ Educates patient for parole or discharge

+ Less potential for waste

+ More confidential?

+ More staff intensive

- More difficult to assess adherence
accurately

- Patients may not learn to be selfsufficient

- Not as good for forgetful patients

- Some patients won't take medications
because they don't want to stand in line

- Potential for increased waste

- Less confidential?
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CASE STUDY - Multi-drug Resistant Tuberculosis

By Tanvir K. Bell, M.D.*

CASE: A 35-year-old female prisoner presented to the infirmary with a complaint of fever and 22-pound weight loss. She denied cough, nausea, emesis, headache, diarrhea, skin rash, or recent change in medication. She stated that she had received treatment for tuberculosis several times over the past ten years, none by directly observed therapy (DOT). She states that she has never completed more than six consecutive months of treatment.
The patient's examination was notable for wasting, thrush, and a purulent cervicitis. Her chest x-ray demonstrated right hilar adenopathy.
Laboratory results revealed a hemoglobin of 10.8, WBC of 2900 with lymphocytopenia, and serum albumin of 2.9. A urinalysis revealed 25 white
blood cells, and 10 red blood cells. The patient was placed in the infirmary and treated with ceftriaxone and azithromycin.
Blood and urine cultures were negative. A urine specimen was positive for chlamydia and gonorrhea by ligase chain reaction. A HIV antibody
test was strongly reactive, and a CD4 count was 27/mm. Three sputum smears were negative for AFB. On the twelfth day, growth in broth was
detected for one out of three specimens. A gene probe for tuberculosis was positive. Because of the patient's history of multiple prior incomplete courses for therapy for TB, she was started on five drugs (INH, rifampin, PZA, ethambutol, and ofloxacin). After seven weeks, the susceptibility report was received demonstrating resistance to both INH and rifampin. Her regimen was changed to include four drugs to which her
isolate was susceptible, administered by strict DOT.
DISCUSSION: Human Immunodeficiency Virus (HIV) increases the
risk of reactivating latent Mycobacterium tuberculosis (MTB) and also
increases the risk of rapid MTB progression. The presentation of tuberculosis in the HIV-infected patient is variable. Radiographic findings
are often atypical in that they may not demonstrate classic upper lobe
cavitary lesions. In some series, the most common chest x-ray finding
is hilar fullness without infiltrate.

and IDSA have compiled guidelines to the "Treatment of Tuberculosis"
that appeared in the Morbidity and Mortality Weekly Report on June
20, 2003. This comprehensive guide is designed to help providers
managing TB. If a patient needs modification of his treatment regimen
due to failure, at least two drugs should be added to a failing regimen
until susceptibilities return. Some drugs may require levels be checked
and some may require dose-adjustment for renal insufficiency.

MTB infection may lead to significant morbidity and mortality, yet it is a
preventable and treatable disease. Multi-drug resistant tuberculosis
(MDR TB) is defined as MTB that is resistant to at least isoniazid and
rifampin. MDR TB is often more challenging to treat, and is more likely to be fatal.

Treatment of the HIV- and TB-coinfected patient can be challenging. In
a study of HIV-infected individuals infected with tuberculosis in Greater
London and Southeast England by G. L. Dean and his colleagues,
54% (99/183) of patients experienced adverse events during HIV and
TB therapy. One-third of patients had to interrupt or change therapy.
The most common adverse events included peripheral neuropathy
(21%), rash (17%), and gastrointestinal upset (10%). These most often
occurred in the first two months of therapy. Patients with CD4 counts
> 100/mm were unlikely to experience AIDS defining illnesses during
the course of therapy, so the authors concluded that the initiation of
HAART therapy should be deferred until the first two months of TB
therapy is completed. An Italian study showed that HAART therapy
after TB diagnosis is associated with a decreased risk of death; while
older age, CD4+ cell count < 25/mm3, and an AIDS-defining illness
before TB diagnosis were associated with a higher risk of death.

The percentage of tuberculosis cases in the United States due to MDR
TB increased from 2% to 9% in the 1990s. Resistance is not uniformly distributed, but is more common in large urban areas and coastal or
Southern border communities. In Los Angeles, one survey revealed
that resistance rates were higher for Hispanics, Asians, and Blacks
than for Whites. Southeast Asian countries have a higher prevalence
of MDR TB than do African countries. Among immigrants from endemic areas, the risk of MDR TB is greatest during the first few years after
immigration and then decreases to a rate similar to that seen in general population. Epidemics of MDR have been described among those
with Human Immunodeficiency Virus (HIV) infection as well as those
without HIV or AIDS. Epidemics have also been described in nosocomial settings. In a group of 62 patients with MDR TB in Florida, risk factors among those with HIV infection included homosexuality, AIDS,
and previous hospitalization on an inpatient HIV ward. The median survival for AIDS patients during this outbreak was 1.5 month vs. 14.8
months for HIV-infected patients without AIDS.
MDR mutants occur as a result of failure to kill random preexisting
mutations. A mutant can occur as a consequence of monotherapy,
irregular administration, neglect in taking one or more of the prescribed
drugs, poor absorption, or insufficient number of active agents in the
regimen. Patients who are at increased risk of relapse are those who
have cavitation on initial chest radiograph and those who have a positive culture after completing two months of therapy.
TB susceptibility results may not be available for up to two months.
Smear negative specimens can take longer to yield a positive culture,
therefore delaying susceptibility testing. Obtaining susceptibility results
and using them to modify treatment in a timely manner is essential to
effective treatment and to limiting the development of further drug
resistance.
Usual MTB empiric therapy as recommended by the CDCP, American
Thoracic Society (ATS), and the Infectious Diseases Society of
America (IDSA) includes isoniazid, rifampin, pyrazinamide, ethambutol. Medication options for those who have MDR TB include streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, ciprofloxacin,
ethionamide, aminosalicylic acid, and cycloserine. The CDCP, ATS,

Drug interactions complicate treatment of patients co-infected with HIV
and tuberculosis. Two medications that commonly cause drug interactions are rifampin and ritonavir. The same premise of adherence as a
way to decrease the emergence of MDR TB holds true as the key to
success for Highly Active Anti-retroviral Therapy (HAART). Adherence
to treatments that may include more than 20 pills each day is very challenging and requires close monitoring by experienced providers.
Treatment outcomes vary among patients with MDR-TB. Response
depends on the extent of pulmonary involvement, the number of bactericidal drugs used, community resources available, and the patient's
ability to comply and tolerate therapy. Reported success rates have
varied between 60% and 95% in selected groups.
Prevention is still key to reduce the spread of tuberculosis and is
emphasized for the control of MDR-TB. Directly Observed Therapy
(DOT) has aided in the effort to ensure compliance of therapy for TB
and prevent the emergence of MDR TB. It is also essential to recognize risk factors of prior noncompliance to therapy or being in or from
an epidemic area for MDR-TB. The recent treatment guidelines in the
June 2003 issue of the MMWR are a valuable resource to be used in
the treatment of tuberculosis. Cooperation with public health departments and experts in the management of HIV and TB is essential to
the success of treatment of the HIV and MTB- co-infected patient.
Disclosures:
*Speaker's Bureau: Gilead, GlaxoSmithKline, Bristol-Myers Squibb
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Clustering for Care and the Civil Rights of HIV-Infected Inmates

Abby Dees, J.D.*, Interim Director of Correct HELP - The Corrections HIV Education & Law Project
Mary Sylla, J.D.**, Founding Director of Correct HELP

Last year, a group of segregated HIV-infected inmates filed a
class action lawsuit against the Limestone Correctional Facility in
Alabama. Their complaint - unconstitutional medical treatment
and living conditions - paints a disturbing picture of gross neglect
and poor medical care. The controversy surrounding this lawsuit
has focused new attention on the issue of clustering, or grouping
or segregating HIV-infected inmates to provide specialized treatment and management. While many medical service providers
support clustering as a tool to provide skilled, centralized care for
HIV-infected inmates, many prisoners' rights advocates argue
that clustering raises serious civil rights issues, such as those
alleged in the Limestone case.
Practical Aspects of Clustering
The primary goal of clustering is to create centers of excellence
that promote HIV expertise. By bringing together all HIV-infected
inmates, a prison may dedicate staff and resources to their care,
and ensure up-to-date medical treatment. Likewise, inmates benefit from living in therapeutic communities, with peer support and
improved patient education, relatively free from the threat of
harassment from other inmates. Clustering may also reduce HIV
transmission among inmates and promote increased HIV testing
and disclosure, since inmates know that they will receive better
care if they seek help.
Opponents of clustering laud these goals, but say they are unrealistic in practice. Since prison health care is, in some cases,
underfunded, and overtaxed by patient need, opponents doubt
that the goal of excellence (comparable to outside facilities) can
be met, even with the increased efficiency of clustering.
Additionally, clustering may actually discourage disclosure and
testing because segregated HIV-infected inmates are often
denied full and equal access to coveted work and education programs. As HIV treatment continues to improve and HIV-infected
individuals live healthier lives with only routine monitoring, clustering may become increasingly outdated.
It is important to note that clustering can take a number of different forms. Some states may simply designate that all known HIVinfected inmates be housed in general population at specific facilities to obtain centralized treatment and better use of medical
resources; others may provide separate dorms or units within
general population, and still others that may totally segregate HIVinfected inmates from general population. Currently, Alabama is
the only state that has an official policy of segregating HIV-infected inmates. As will be discussed below, the legal implications of
clustering depend greatly on the extent to which HIV-infected
inmates are treated differently than HIV-uninfected inmates of the
same security level.
Legal Issues Raised by Clustering
The two main areas of the law that address the issue of clustering are the 8th Amendment of the Constitution and anti-discrimination disability statutes. The 8th Amendment, which prohibits
cruel and unusual punishment, establishes the baseline for
inmate medical care: staff must not be deliberately indifferent to
an inmate's serious medical needs. This is a very low standard
that requires staff simply to refrain from knowingly allowing an
inmate to suffer great harm. Not surprisingly, the 8th Amendment
gives facilities great latitude to establish their own HIV treatment
protocols. So far, none of the high courts have interpreted the 8th
Amendment to mean that an HIV-infected inmate should see an
HIV specialist. The goal of clustering for HIV care thus far

exceeds any constitutionally-mandated level of care - a fact justly
celebrated by proponents.
However, clustering can be problematic when challenged under
statutes that prohibit discrimination on the basis of disability, such
as the Americans with Disabilities Act. These laws require that
HIV-infected inmates have equal access to prison programs for
which they are "otherwise qualified." In the 1999 case of Onishea
v. Hopper (171 F.3d 1289), the 11th Circuit Court of Appeals held
that HIV-infected inmates could be segregated for legitimate
penological reasons (e.g., security or efficiency), but that prisons
were still required to make a good faith effort, or "reasonable
accommodation" to provide equal access to programs and services. The court stipulated that prisons should not have to bear
an enormous cost burden to provide equal access, but did not
state as a matter of law what particular accommodations were
required.
This gray area means that prisons still have little guidance about
what constitutes a reasonable accommodation. Anti-discrimination laws in the prison context are therefore still in a tremendous
state of flux.
So, the most basic operating principle is this: the more that clustering results in reduced access to prison programs and services,
the more vulnerable a prison can be to litigation. If clustering can
be accomplished with minimal impact on inmates' access to programs and services, inmates may be more likely to disclose their
status, seek testing, and otherwise gain the benefits of a clustering system. These programs may, therefore, pass muster under
anti-discrimination laws if challenged in the courts.
Finally, clustering raises the issue of the right to privacy under the
1st Amendment. In many facilities, clustered inmates can be
identified by other inmates, thereby revealing their status. While
inmates do have a basic right to privacy, courts have held that
legitimate penological concerns, such as inmate health and wellbeing, outweigh these privacy interests.
Clustering and Mandatory Testing
Another factor to consider is how effective clustering can be in
states without mandatory testing. Inmates who choose not to
seek testing or disclose their HIV status out of fear of segregation
are effectively cut off from HIV care and counseling, possibly
increasing the risk of transmission to other inmates. However, if
facilities can design clustering programs that try to meet the
requirements of anti-discrimination laws, inmates may be much
more likely to seek proper care in those states that do not have
mandatory testing.
Conclusion
In a perfect world, HIV-infected inmates would have access to
expert treatment and equal opportunities to participate in prison
programs, and the law strives for something like this. However,
the reality of prison life and limited funds can thwart these goals.
The best compromise may be a truly individualized system that
allows those HIV-infected inmates who need highly focused medical attention to receive it, perhaps through inmate clustering,
while those who can fully participate in prison programs be
allowed to do so.
Disclosures:
*Nothing to disclose.
**Nothing to disclose.
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Save the
Dates
OraQuick Rapid HIV-1 Antibody
Test Seminar
November 4, 2003
Raleigh, North Carolina
Topics: HIV-Test Related
Counseling; Oral HIV Antibody
Testing; Partner Notification; Rapid
HIV Antibody Testing.
Contact: Community Service
Network, Inc.
Call: 910.892.8128
Fax 910.892.813;
Email: CSN@dockpoint.net

ICAAC & IDSA Update
November 7, 2003
Boston, Massachusetts
Topics: Adverse Reactions;
Antiretroviral Drugs; Drug
Resistance; HIV/AIDS Treatment or
Therapies; Metabolic Diseases or
Disorders
Contact: NEAETC
Call: 617.262.5657
Fax: 617.262.5667
Email: aidsed@neaetc.org
www.neaetc.org/_Programs/2003/
11November/07ICAAC_IDSA.htm.
Antiretrovirals: From the Street
to the Gut to the Cell
November 7, 2003
Worcester, Massachusetts
Topics: Antiretroviral Drugs; Drug
Resistance; HIV/AIDS Treatment or
Therapies; Metabolic Diseases or
Disorders; Patient Care
Call: 800.366.9034
Inside and Out: HIV and
Corrections
December 5, 2003
Radisson Hotel
Marlborough, Massachusetts
A conference to increase knowledge, awareness and understanding of HIV infection in correctional
and post-correctional settings.
Contact: Andy Diamond
Call: 617.450.1264
Fax: 617.437.6445
Email: adiamond@aac.org
The 11th Conference on
Retroviruses and Opportunistic
Infection
February 8-11, 2004
San Francisco, California
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
www.retroconference.org
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Inside News
CDC Broadcast: "Preparing for the Return of
SARS: Are we ready?"
This public health training live satellite broadcast assists healthcare providers in preparing to
diagnose and manage patients with SARS
should cases be suspected or identified in the
coming months. This two-part training session
aims to provide updated information required to
identify and manage patients with SARS, and to
prevent transmission of SARS in healthcare
facilities and the community. Program details
can be viewed at www.phppo.cdc.gov/
PHTN/SARS-return.
CDC, 9/11/03
Merck Starts Global Human Trial of HIV
Vaccine
Merck & Co. announced that it has started the
first global human trials of an experimental AIDS
vaccine, in collaboration with Seattle-based HIV
Vaccine Trials Network. This study, which is
being conducted in 18 cities in North America,
South America, the Caribbean, southern African
and southeast Asia, includes about 435 adult
volunteers not infected with HIV. The goal of the
trials is to determine whether the vaccine candidate is safe, has tolerable side effects, is practical to administer in different areas of the world,
and stimulates an immune response. Diverse
testing sites are critical, as different strains of
HIV circulate in different regions. Since the vaccine is made from a modified cold virus, and
does not contain any live HIV, there is no risk of
causing HIV infection.
Associated Press, 9/19/03
FDA Approves Schering Drug for
Hepatitis C
Schering-Plough Corporation said it had
received Food and Drug Administration
approval for a prefilled penlike syringe that
administers a drug for chronic hepatitis C. The
device, the PEG-Intron Redipen, was designed
to be simpler to use than a traditional vial and
syringe. Schering-Plough, based in Kenilworth,
N.J., said it expected to make the product available in the United States in early 2004. It is
already available in Europe and other international markets.
New York Times, 10/14/03

Study: Switching from a PI to an NNRTI is
Safe for Patients with Undetectable Viral
Load
An article in the New England Journal of
Medicine (NEJM) presents data that suggests
treatment regimens containing nevirapine or
efavirenz offer comparable efficacy and safety
to patients with an undetectable viral load who
switched from a protease inhibitor- (PI) based
regimen. Both are non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are used in
combination with other antiretroviral therapies to
treat patients with HIV-1 infection. The nucleoside reverse transcriptase inhibitor (NRTI), abacavir, was also evaluated in the study.
According to investigators, there was a trend
towards higher failure rates in patients who
switched to abacavir. The results of the study
are significant because physicians are seeking
alternatives to PI regimens due to their high pill
burden and food restrictions or concerns about
metabolic side effects.
www.aegis.org/news/pr2003/PR030923.html
Study: DOT Does Not Ensure HIV Treatment
Adherence
Directly observed therapy (DOT) for HIV infection is commonly used in correctional settings;
however, the efficacy of DOT for treating HIV
infection has not been confirmed. A study from
the University of North Carolina at Chapel Hill
assessed adherence to antiretroviral therapy
regimens among 31 HIV-infected prison
inmates who were receiving > 1 antiretrovirals
via DOT. Adherence was measured by selfreport, pill count, electronic monitoring caps,
and, for DOT only, medication administration
records. Objective methods of measurement
revealed that adherence to antiretroviral regimens administered wholly or in part by DOT
was < or = 90% in more than one-half of the
patients. Different methods used to measure
adherence revealed significantly different levels
of adherence. These findings suggest that use
of DOT does not ensure adherence to antiretroviral therapy.
Division of Infectious Diseases, Department of
Medicine, University of North Carolina at Chapel
Hill

SARS Resources
World Health Organization (WHO)
www.who.int/csr/sars/en/
Centers for Disease Control and Prevention
(CDC), www.cdc.gov/ncidod/sars/

National Library of Medicine
www.nlm.nih.gov/medlineplus/
severeaccuterespiratorysyndrome.html
TRAIN.org
www.TRAIN.org
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through May 31,2004.
The estimated time for completion of this activity is one hour and there is no fee for participation.

1. The incidence of HIV-associated opportunistic infections is
lower in incarcerated HIV-infected patients than in those who are
not incarcerated.
a) True
b) False
2. The introduction of HAART has resulted in which of the
following?
a) An increase in the number of patients living with AIDS
b) Prevention of the immunological abnormalities associated
with HIV infection
c) A decline in the rates of HIV-related deaths and OIs
d) All of the above
3. Secondary prophylaxis is instituted:
a) before the occurrence of an OI
b) at the onset of an OI
c) after the first episode of illness, to prevent recurrences
d) depending upon the type of OI
4. One advantage to Keep On Person (KOP) Therapy vs.
Directly Observed Therapy (DOT) is:
a) KOP improves the ability of clinicians to assess for
adherence
b) KOP methods increases a patient's control over his or
her therapy
c) KOP methods are better for patients who often forget to
take their medication
d) KOP methods eliminate the likelihood of waste of
medications
5. Currently, the only state that has an official policy of segregating HIV-infected inmates is:
a) Georgia
b) Florida
c) Alabama
d) Texas

6. Multi-drug resistant tuberculosis (MDR TB) is defined as
tuberculosis that is resistant to at least:
a) isoniazid and rifampin
b) rifampin and clarithromycin
c) ethionamide, aminosalicylic acid, and cycloserine
d) isoniazid and ciprofloxacin

HEPP Report Evaluation
5 Excellent

4 Very Good

3 Fair

2 Poor

1 Very Poor

1. Please evaluate the following sections with respect to:
educational value

clarity

Main Article

5 4 3 2 1

5 4 3 2 1

Inside News
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Save the
Dates

5 4 3 2 1

5 4 3 2 1

2. Do you feel that HEPP Report helps you in your work?
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5. Do you have specific comments on this issue?

BROWN MEDICAL SCHOOL • OFFICE

OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education activities for physicians.
The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations
and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the
Brown Medical School.

For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree
Address

____________________

____________________________________________________________________________________________

____________________________________________________________________________________________________
City

____________________________________________________ State

________ Zip ________________________

Telephone ________________________________________________ Fax ______________________________________

